BMS-986165 phase 2 Trial results

[Fred]

Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial.

Quote:

---

Bristol-Myers Squibb Company today announced results from a Phase 2 study of BMS-986165, an investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis. Efficacy endpoints including ≥75% and 90% reduction in the Psoriasis Area and Severity Index (PASI 75, PASI 90) were achieved following 12 weeks of treatment with ≥3 mg daily of BMS-986165, with a favorable risk-benefit profile. Nasopharyngitis, headache, diarrhea, nausea and upper respiratory tract infection were the most common adverse events (AEs) reported.  

“Moderate to severe psoriasis remains undertreated and many patients struggle with insufficient disease control, leaving a significant need for effective and convenient therapies that can provide a positive impact on patients' lives,” said Mary Beth Harler, M.D., head of Innovative Medicines Development, Bristol-Myers Squibb. “BMS-986165 is a novel, oral, selective TYK2 inhibitor with a distinct mechanism of action that has the potential to help psoriasis patients control their disease, and is planned for study in a wide spectrum of immune-mediated diseases.”

“Currently, patients with moderate to severe psoriasis have a limited number of oral therapies,” said Dr. Kim Papp, M.D., Ph.D., of Probity Medical Research in Waterloo, Ontario and lead author of the New England Journal of Medicine publication. “Having a favorable risk-benefit profile and delivering significant skin clearance and improvements in quality of life measures, these data suggest that BMS-986165 may be a promising oral option to help patients control their psoriasis in the future.”

The registrational POETYK (PrOgram to Evaluate the efficacy and safety of BMS-986165, a selective TYK2 inhibitor) PSO Phase 3 program for patients with moderate to severe plaque psoriasis is currently enrolling. Phase 2 trials for patients with systemic lupus erythematosus or Crohn's disease are also ongoing.

Source: Bristol-Myers Squibb

[Caroline]

Interesting an oral biological !

[Caroline]

If you look into the BMJ journal, you see the description of it.
What struck me was this figure on the lymphocytes.





It was accompanied by the text “BMS-986165 demonstrated dose-dependent inhibition of lymphocyte count decreases and expression of 53 IRGs in blood (Figure 1).”

But..... unfortunately that is a too high form of English for me. I cannot grasp what they mean in relation to the figure. Can someone translate this for me into real understandable English?

When I interpret the figure then I see globally that the use of BMS-numberbla, pushes the lymphocyte count downward. But........ it is a misleading conclusion as it seems that a higher dose, does less push lympho count down than the lower dose...
Even what is startling is that the placebo seems to push down the lympho count most. 
This cannot be true... 
so there is some sneaky combination of text and figure that puts me in trouble....

Bill !!! Heeelp !

[Bill]

I tried to make sense of the figure, Caroline. It looks as if the placebo caused the biggest drop in lymphocytes. That seems wrong. The accompanying commentary suggested that what was being sought was a dosage that would suppress specific immune cells sufficiently without causing a neutropenia. The bar chart below the figure you posted looked more informative.

Cheers